Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis
Abstract Background Activation of melanocortin 1 receptor (MC1R) is known to exert broad anti-inflammatory and anti-fibrotic effects. The purpose of this study is to investigate the potential of dersimelagon, a novel oral MC1R agonist, as a therapeutic agent for systemic sclerosis (SSc). Methods The...
Main Authors: | Masahiro Kondo, Tsuyoshi Suzuki, Yuko Kawano, Shinji Kojima, Masahiko Miyashiro, Atsuhiro Matsumoto, Gabriela Kania, Przemysław Błyszczuk, Rebecca L. Ross, Panji Mulipa, Francesco Del Galdo, Yun Zhang, Jörg H. W. Distler |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-09-01
|
Series: | Arthritis Research & Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13075-022-02899-3 |
Similar Items
-
Melanogenic effect of dersimelagon (MT‐7117), a novel oral melanocortin 1 receptor agonist
by: T. Suzuki, et al.
Published: (2022-03-01) -
Regulation of Melanocortin-3 and -4 Receptors by Isoforms of Melanocortin-2 Receptor Accessory Protein 1 and 2
by: Ren-Lei Ji, et al.
Published: (2022-02-01) -
Modulation of Canine Melanocortin-3 and -4 Receptors by Melanocortin-2 Receptor Accessory Protein 1 and 2
by: Ren-Lei Ji, et al.
Published: (2022-11-01) -
Melanocortin 1 Receptor: Structure, Function and Regulation
by: Erin Marissa Wolf Horrell, et al.
Published: (2016-05-01) -
Editorial: Melanocortins and melanocortin receptors in the regulation of inflammation: mechanisms and novel therapeutic strategies
by: Petteri Rinne, et al.
Published: (2023-05-01)